Showing results (191-200 of 212) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2018
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid TumorsDaniel D Von Hoff, Drew W Rasco, Elisabeth I Heath, et al.
The New England Journal of Medicine|October 18, 2013
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineDaniel D Von Hoff, Thomas Ervin, Francis P Arena, et al.
Frontiers in Oncology|December 21, 2020
Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Early DetectionMohamed Zaid, Dalia Elganainy, Prashant Dogra, et al.
The Oncologist|June 10, 2026
A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM) and paricalcitol as neoadjuvant therapy in pancreatic cancerAlexa F Viniotis, Gayle S Jameson, Betsy C Wertheim, et al.
Clinical Therapeutics|April 5, 2016
Patient-reported Symptoms of Tenosynovial Giant Cell TumorsHeather L Gelhorn, Sandra Tong, Kelly McQuarrie, et al.
Oncotarget|June 12, 2020
An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinomaKatherine M Bever, Erkut H Borazanci, Elizabeth A Thompson, et al.
Cancer Cell|October 6, 2023
Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancerNirakar Rajbhandari, Michael Hamilton, Cynthia M Quintero, et al.
Investigational New Drugs|September 29, 2018
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastasesHani M Babiker, Sara A Byron, William P D Hendricks, et al.
Biorxiv : the Preprint Server for Biology|September 25, 2023
Inhibiting Stromal Class I HDACs Curbs Pancreatic Cancer ProgressionGaoyang Liang, Tae Gyu Oh, Nasun Hah, et al.
Nature Communications|December 6, 2023
Inhibiting stromal Class I HDACs curbs pancreatic cancer progressionGaoyang Liang, Tae Gyu Oh, Nasun Hah, et al.
Pageof 22